Neurogenesis-Associated Protein, a Potential Prognostic Biomarker in Anti-PD-1 Based Kidney Renal Clear Cell Carcinoma Patient Therapeutics
- 1State Key Laboratory of Systems Medicine for Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- 2Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- 0State Key Laboratory of Systems Medicine for Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Transketolase 1 (TKTL1) impacts kidney cancer prognosis and immune cell infiltration, particularly in clear cell renal cell carcinoma (KIRC). TKTL1 may predict response to anti-PD-1 therapy, with piperine and glibenclamide identified as potential agonists.
Area Of Science
- Oncology
- Immunology
- Pharmacology
Background
- Transketolase 1 (TKTL1) is crucial for brain development and implicated in cancers.
- Its role in kidney cancer prognosis and immune cell infiltration is largely unexplored.
- Understanding TKTL1's function is vital for developing novel kidney cancer therapies.
Purpose Of The Study
- To investigate TKTL1 expression, its clinical significance, and its association with immune infiltrates in kidney cancer.
- To explore TKTL1's role in predicting response to anti-PD-1 immunotherapy in renal cancer.
- To identify and validate TKTL1 agonists for potential therapeutic applications.
Main Methods
- Utilized various databases and TIMER to analyze TKTL1 expression and immune cell infiltration across cancer types.
- Performed virtual screening of natural compounds and alkaloids to identify TKTL1 agonists.
- Conducted in vitro cell viability and colony formation assays to confirm the efficacy of identified agonists.
Main Results
- TKTL1 expression significantly impacts prognostic potential in kidney cancer subtypes.
- TKTL1 positively correlates with immune cell infiltration in kidney renal clear cell carcinoma (KIRC), potentially via the mTOR pathway.
- TKTL1 acts as an immunomodulator in KIRC patients' response to anti-PD-1 therapy.
- Piperine and glibenclamide were identified as potent TKTL1 agonists, inhibiting Caki-2 cell proliferation in vitro.
Conclusions
- TKTL1 is a promising prognostic biomarker for KIRC, especially for predicting response to anti-PD-1 therapy.
- Piperine and glibenclamide demonstrate therapeutic potential as TKTL1 agonists for kidney cancer treatment.
- This study provides a theoretical basis for utilizing TKTL1 modulation in clinical kidney cancer management.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

